Stabilis
Nitroprusside sodium
Noms commerciaux
Nipride Canada, Pays bas Nipruss Allemagne, Egypte
Nitropress Etats Unis d’Amérique, Iran, Nouvelle Zélande
Stabilité des solutions
0,05 & 0,1 mg/ml 25°C 48 1037
0,05 & 0,1 mg/ml 25°C 48 1037
0,05 & 0,1 mg/ml 25°C 48 1037
0,05 & 0,1 mg/ml 25°C 48 1037
0,001 mg/ml 20°C 264 2028
0,001 mg/ml 4°C 264 2028
0,5 & 1,67 mg/ml 25°C 12 633
1 mg/ml 25°C 24 196
1 mg/ml 4°C 9 3903
Stabilité en mélange
0,4 mg/ml 22°C-23°C Milrinone lactate : 0,2 mg/ml 4 813 0,05 & 0,4 mg/ml ? Ranitidine hydrochloride : 0,05 & 2 mg/ml 48 210
1,2 mg/ml 22°C Dobutamine hydrochloride : 5 mg/ml 24 3381
0,18 mg/ml 25°C Sodium thiosulfate : 1,8 mg/ml 48 4020
0,2 mg/ml 15-30°C Esmolol hydrochloride : 10 mg/ml 24 363
0,18 mg/ml 25°C Sodium thiosulfate : 1,8 mg/ml 48 4020
Facteur influençant la stabilité
196 1151 1316 1379 3177 3381
Incompatibilités
Nitroprusside sodium : 1,2 mg/ml
Amiodarone hydrochloride : 12,5 mg/ml 2879
Nitroprusside sodium : 2 mg/ml
Cisatracurium besylate : 2 & 5 mg/ml 299
Nitroprusside sodium : 1,2 mg/ml
Dobutamine hydrochloride : 5 mg/ml 2879
Nitroprusside sodium : 1,2 mg/ml
Dopamine hydrochloride : 5 mg/ml 2879
Nitroprusside sodium : 0.2 mg/ml
Haloperidol lactate : 5 mg/ml 403
Nitroprusside sodium : 10 mg/ml
Levofloxacine : 5 mg/ml 1072
Nitroprusside sodium : 0.4 mg/ml
Oritavancin : 0.8 >>2 mg/ml 3152
Nitroprusside sodium
Pantoprazole sodium 2090
Nitroprusside sodium : 1.2 mg/ml
Sodium thiosulfate : 10 mg/ml 3381
Nitroprusside sodium : 10 mg/ml
Thiopental sodium : 25 mg/ml 3767
Voie d’administration
Bibliographie
Type Source
196 Revue Pramar Y, Das Gupta V, Neal Gardner S, Yau B.
Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes.
J Clin Pharm Ther 1991 ; 16: 203-207.
210 Revue Stewart JT, Warren FW, King AD.
Stability of ranitidine hydrochloride and seven medications.
Am J Hosp Pharm 1994 ; 51: 1802-1807.
299 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
363 Revue Karnatz NN, Wong J, Baaske DM, Johnson JH, Speicher ER, Herbranson DE.
Stability of esmolol hydrochloride and sodium nitroprussiate in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 101-104.
403 Revue Outman WR, Monolakis J.
Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 1539-1541.
633 Revue Sewell GJ, Forbes DR, Munton TJ.
The stability of sodium nitroprusside infusion during administration by motorized syringe-pump.
J Clin Hosp Pharm 1985 ; 10: 351-360.
813 Revue Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68.
1037 Revue Mahony C, Brown JE, Stargel WW, Verghese CP, Bjornsson TD.
In vitro stability of sodium nitroprusside solutions for intravenous administration.
J Pharm Sci 1984 ; 73: 838-839.
1072 Revue Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1109 Revue Horrow JC, Digregorio J, Barbieri EJ, Rupp E.
Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible.
Crit Care Med 1990 ; 18: 858-861.
1151 Revue Baaske DM, Smith MD, Karnatz N, Carter JE.
High-performance liquid chromatographic determination of sodium nitroprusside.
J Chromatogr 1981 ; 212: 339-346.
1316 Revue Davidson SW, Lyall D.
2028 Revue Kaisserlian CE, Razzouq N, Astier A, Paul M.
Sodium nitroprusside stability at 1 µg/ml in aqueous solutions.
EJHP Science 2005 ; 11, 4: 88-90.
2090 Revue Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2879 Poster Imesch G., Humbert-Delaloye V., Berger M., Pannatier A.
Compatibilité entre amiodarone, catecholamines et/ou nitroprussiate de sodium, administré en continu par voie veineuse aux soins intensifs adultes.
GSASA Congress - Lucerne - Switzerland 2008 3152 Revue Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3177 Poster Humbert-Delaloye V, Berger M, Pannatier A.
Compatibilités physico-chimique entre catécholamines, amiodarone, et/ou nitroprussiate de sodium intraveineux.
16èmes JFSPH, Sion, 18-19 novembre 2010 2010
3381 Revue Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A.
In vitro compatibility of various cardioactive drugs during simulated Y-site administration.
EJHP 2013 ; 20:110-116.
3767 Revue Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3903 Revue Anderson Collin R, Collins D, Laursen T, Arave T, Helm M.
Stability of Sodium Nitroprusside in 5% Dextrose Stored at 4°C in Polypropylene Syringes Protected from Light.
Int J Pharm Compound 2016 ; 20, 5 : 435-437.
4020 Revue T. Schulz L, J. Elder E, Jones K, Vijayan A, D. Johnson B, E. Medow J, Vermeulen L.
Stability of Sodium Nitroprusside and Sodium Thiosulfate 1:10 Intravenous Admixture.
Hosp Pharm 2010 ;45,10:779?784
